Sugi Predict

Sugi Predict / Compounds / SCHEMBL16668472

SCHEMBL16668472

SCHEMBL16668472

C[C@H](COCC(=O)O)NC(=O)OC(C)(C)C

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.46
▸ CA2 P00918 1/20 0.46
▸ CA7 P43166 1/20 0.46
▸ CTSK P43235 10/20 0.43
▸ CTSS P25774 7/20 0.43
▸ PPARA Q07869 2/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ CTSL P07711 1/20 0.41
▸ CTSB P07858 1/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ PPARG P37231 1/20 0.40
▸ ATM Q13315 1/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL321141 1.00 CA1 (0.46) CA1CA2CA7CTSKCTSS
SCHEMBL16668258 1.00 CA1 (0.46) CA1CA2CA7CTSKCTSS
SCHEMBL19084258 0.88 CA1 (0.53) CA1CA2CA7CTSKCTSS
SCHEMBL23297026 0.87 CYP2D6 (0.49) CA1CA2CA7CTSKCTSS
SCHEMBL23297024 0.87 CYP2D6 (0.49) CA1CA2CA7CTSKCTSS
SCHEMBL31390882 0.84 CA1 (0.44) CA1CA2CA7CTSKCTSS
SCHEMBL31074181 0.84 CA1 (0.44) CA1CA2CA7CTSKCTSS
SCHEMBL19041565 0.83 CA1 (0.49) CA1CA2CA7CTSKCTSS
SCHEMBL89821 0.83 CA1 (0.49) CA1CA2CA7CTSKCTSS
SCHEMBL90187 0.83 CA1 (0.49) CA1CA2CA7CTSKCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025067457-A1 HETEROCYCLIC FUSED RING COMPOUND, AND COMPOSITION AND USE THEREOF 深圳市塔吉瑞生物医药有限公司 2025-04-03 — — WO disclosed
EP-3060563-B1 RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS NOVARTIS AG (CH) 2018-05-02 — — EP disclosed
US-9896449-B2 Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors NOVARTIS AG (CH) 2018-02-20 — — US disclosed
US-20170066766-A1 Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors NOVARTIS AG (CH) 2017-03-09 — — US disclosed
US-9533988-B2 Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors NOVARTIS AG (CH) 2017-01-03 — — US disclosed
US-20160102092-A1 Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors NOVARTIS AG (CH) 2016-04-14 — — US disclosed
US-9266883-B2 Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors NOVARTIS AG (CH) 2016-02-23 — — US disclosed
US-20150119385-A1 Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors NOVARTIS AG (CH) 2015-04-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119385-A1 Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors FGFR4, FGFR1, FGFR3 CA1 4201/4885CA2 1472/4885CA7 2575/4885
US-20160102092-A1 Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors FGFR4, FGFR1, FGFR3 CA1 4201/4885CA2 1472/4885CA7 2575/4885
US-20170066766-A1 Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors FGFR4, FGFR1, FGFR3 CA1 4201/4885CA2 1472/4885CA7 2575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.